Helix Biotech, Inc.’s Post

Translational models matter more than you think. In 2023 alone, 1,958,310 oncology #CRISPR-like screens were performed in the US by Mother Nature. Biopsies from these cancer diagnoses provide snapshots of tumor biology, revealing the genes driving cancer—but what about drug targets? Since in vitro screens often fail to translate into clinical efficacy, could matching drug targets to tumor types based on in vivo #CRISPR-like screens be the answer? At Gordion, we believe it is. Mother Nature’s #CRISPR-like screens can guide translational model selection and represent an opportunity to improve clinical response rates. Learn more about translating #CRISPR-like screen data into clinical success at www.gordion.bio

For National #CancerResearch month, we want to highlight some researchers doing amazing work with 3D cell models in #PrecisionMedicine and #oncology using the #PuMAsystem    First is Dr. Renumathy Dhanasekaran (Stanford University). The goal of Dr. Dhanasekharan’s research is to understand the molecular pathogenesis of #liver cancer and identify biologically relevant prognostic biomarkers and molecular targets for therapy in patients with hepatocellular carcinoma (HCC).    💡 Learn more about her research: https://lnkd.in/daD3sYjQ 

🔬 Researchers at the University of North Carolina at Chapel Hill have made a significant discovery in cancer research, finding that some cancer cells can bypass the drug palbociclib, designed to stop cell proliferation. 🧬 They identified that the enzyme APC/C regulates protein degradation crucial for controlling the cell cycle, and variations in its activity can affect patient responses to treatment. 🔄 The study also revealed that cancer cells can use alternate pathways to continue growing despite the drug, highlighting the need to understand these escape mechanisms. 💡 Understanding these mechanisms could lead to better treatment strategies and improved patient outcomes. Credit: Dianox 📚 Source: https://lnkd.in/dY4ZvrvP #medical #oncology #science #cancerresearch #drugdevelopment

A new publication in Nature Scientific Reports (https://lnkd.in/grDYbGAs), utilizing the #GelCount, has discovered a potential breakthrough in colorectal cancer research. The study reveals that CILP2, a protein, may be a key biomarker for predicting and targeting peritoneal metastases in colorectal cancer. The Korean team used GelCount to count colony formation assays (Figure 4b), providing accurate and reliable data. This discovery could open new avenues in the treatment and management of colorectal cancer and I encourage researchers in the field to read the article for a deeper understanding. #CancerResearch #ColorectalCancer #CILP2 #Biomarker #TherapeuticTarget Asan Medical Center (AMC) University of Ulsan

Scientists at St. Jude Children's Research Hospital - ALSAC have identified 156 potential CAR-T cell therapy targets in brain and solid tumors – providing new possible targets for cancer treatment. The comprehensive analysis included 1,532 pediatric tumor samples and 7,460 normal tissue samples, and revealed cancer-specific genes that can be targeted without harming healthy cells. Amongst the potential targets, researchers have validated their top candidate, COL11A1, through in vivo testing. As the momentum of scientific development into CAR-T therapy grows, building scalable manufacturing solutions is critical to enable widespread patient access and meet the growing demand for advanced therapies. Read more: https://lnkd.in/dY8TkevV #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Reviewing the role of pancreatic cancer exosomes: in this article, Weibin Wang at Chinese Academy of Medical Sciences and collaborators examined current knowledge on how exosomes mediate distant cell-cell communication in pancreatic cancer and discussed their potential clinical applications and future research directions https://lnkd.in/eb6XuGCJ They suggested that combining these biomarkers in a multi-omics approach could significantly enhance the sensitivity and specificity of liquid biopsies. An article co-authored by Cheng Qin, Tianyu Li, Chen Lin, Bangbo Zhao, Zeru Li and Yutong Zhao #extracellularvesicles #exosomes #tumormicroenvironment #liquidbiopsy #pancreaticcancer #Vesiculab

How is IsoPSA able to identify cancer-specific PSA proteins? Our proprietary Solvent Interaction Analysis technology platform (SIA) is changing the world of cancer diagnostics. Tunable to detect underlying cancer biology through protein structure changes, our platform adds accuracy, specificity, and clarity to biomarker measurements. While IsoPSA tests for prostate cancer, future clinical applications of ClevelandDx's SIA platform may include breast cancer, lung cancer, and other cancers. Learn more about our technology here: https://bit.ly/48L2U2R #cancerresearch #cancerdiagnostics #MedEd #FOAMed #prostatecancer

𝗪𝗵𝗮𝘁 𝗿𝗼𝗹𝗲𝘀 𝗱𝗼 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 & 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 𝗽𝗹𝗮𝘆 𝗶𝗻 𝗲𝗮𝗿𝗹𝘆 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀?   Delve deep into the insightful session on “𝗡𝗚𝗦 𝗮𝗻𝗱 𝗖𝗚𝗣 𝗶𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗮𝗻𝗱 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲,” led by Mynn Tan at our recently organized global metaverse conference, OncoVision 2024. Explore how you can integrate such use cases and research studies to make informed decisions for the overall growth of your business by emailing us at contact@iebrain.com.   To know more, visit us: www.iebrain.com. #ebrainOncoVision #cancercare #oncology #immunotherapy #generativeai #nanomedicine #precisiononcology #futureproofingbusinesses

Cell migration and invasion assays are critical tools in cell biology and cancer research, used to study the behavior of cells in response to various stimuli. Migration assays, such as the wound healing (scratch) test and transwell assays, measure how cells move across surfaces or through barriers in response to signals. Invasion assays specifically assess the ability of cells to penetrate extracellular matrices, simulating how cancer cells invade surrounding tissues. Get more on : https://lnkd.in/d2KUr_k8 These assays are pivotal for understanding tumor progression, metastasis, and the effectiveness of potential therapeutic agents, providing insights into the mechanisms driving cell motility and invasion. #CellMigration #CellInvasion #CancerResearch #TumorBiology #CellAssays #InVitroAssays #CellBiology #Metastasis #Biotechnology #PharmaceuticalResearch #CancerTherapy #ResearchInnovation #Oncology #DrugDiscovery

Exciting breakthrough alert! 🚀 New research published in Science Advances sheds light on the critical role of FoxA1 in liver cancer and unveils a potential therapeutic target. Led by Jianping Guo, Lixia Xu, Wei Xie, and Ying Liang, this groundbreaking study uncovers how the inflammatory kinase IKBKE phosphorylates and deactivates FoxA1, promoting liver tumorigenesis. Knock-in mouse models further validate these findings, offering promising insights for future HCC therapies. Proudly partnering with pioneering researchers, SBS Genetech Co., Ltd. supplied the Biotin end-labeled probe used in this study, continuing our legacy of supporting life science innovation since 2000. Join us in driving discovery forward and revolutionizing HCC treatment. #livercancer #researchinnovation #ScienceAdvances 🧬🔬